Teva Pharmaceutical Industries Ltd ADR Stock
The Teva Pharmaceutical Industries Ltd ADR stock is trending slightly upwards today, with an increase of €0.000 (0.350%) compared to yesterday's price.
With 23 Buy predictions and not a single Sell prediction Teva Pharmaceutical Industries Ltd ADR is an absolute favorite of our community.
With a target price of 31 € there is a slightly positive potential of 7.27% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 28.9 €.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | 0.350% | -0.687% | 7.037% | 80.062% | 7.435% | 207.447% | 210.419% |
| Bayer AG ADR | -0.950% | -10.656% | 0.926% | 92.920% | 23.864% | -25.342% | -18.657% |
| UCB S.A. | -1.290% | -4.433% | 5.435% | 49.931% | 14.406% | 230.494% | 232.436% |
| Novartis AG ADR | 1.430% | 1.068% | 14.056% | 35.885% | 19.831% | 74.877% | 97.222% |
Comments
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Barclays PLC from $35.00 to $38.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat